IVIEW Therapeutics Inc. Announces Dosing of First Patient in Phase 1/2 Clinical Trial of IVW-1001 for Dry Eye Disease

By WebmasterJune 25, 2024December 12th, 2024No Comments

IVIEW Therapeutics Inc. Announces Dosing of First Patient in Phase 1/2 Clinical Trial of IVW-1001 for Dry Eye Disease

Previous PostWellsheet AI-Powered Smart EHR UI Delivers Usability and ROI
Next PostAccelerated Biosciences Announces License of its Human Trophoblast Stem Cells (hTSC) to Agathos Biologics for Development of Ethically Sourced Research and Biomanufacturing Platforms